This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Prevention Of Morbidity In Sickle Cell Disease Pilot Phase

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2006 by Institute of Child Health.
Recruitment status was:  Recruiting
Information provided by:
Institute of Child Health Identifier:
First received: December 22, 2006
Last updated: December 23, 2006
Last verified: December 2006
The hypothesis is that in sickle cell anaemia, nocturnal oxyhaemoglobin desaturation, is associated with low processing speed index, and this morbidity can be reduced with overnight auto Continuous Positive Airways Pressure and/or oxygen supplementation.

Condition Intervention Phase
Sickle Cell Anaemia Device: auto Continuous Positive Airways Pressure (CPAP) with oxygen supplementation Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single

Resource links provided by NLM:

Further study details as provided by Institute of Child Health:

Primary Outcome Measures:
  • Change in processing speed index

Secondary Outcome Measures:
  • Frequency of pain measured via SMS and pain diary
  • Adverse events e.g. headache, anorexia, weight loss, nausea, vomiting, reduction in steady state red or white cell count
  • Change in Blood pressure
  • Number of omissions on Conners Continuous Performance Test
  • Change in Chervin sleep Questionnaire
  • Change in Behaviour Rating Inventory of Executive Function (BRIEF)
  • Change in number of abnormalities (Adams’ criteria) on TCD

Estimated Enrollment: 22
Study Start Date: November 2006
Detailed Description:
Intervention: Overnight auto Continuous Positive Airways Pressure (CPAP) with oxygen supplementation if mean overnight oxyhaemoglobin saturation is not >94% after 2 weeks of autoCPAP

Ages Eligible for Study:   4 Years to 16 Years   (Child)
Sexes Eligible for Study:   All

Inclusion Criteria:

  1. Age >4 years.
  2. Informed consent with assent in accordance with UK ethical committee(COREC) system must be signed by the patient's parent or legally authorized guardian acknowledging written consent to join the study. When suitable, patients will be requested to give their assent to join the study.
  3. Haemoglobin SS (homozygous sickle cell anaemia) diagnosed by standard techniques. Participating institutions must submit documentation of the diagnostic haemoglobin analysis.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00415727

Contact: Fenella Kirkham, Dr

United Kingdom
Neuroscience Unit, Institute of Child Health Recruiting
London, United Kingdom, WC1N 1EH
Contact: Fenella Kirkham, Dr   
Principal Investigator: Fenella Kirkham, Dr         
Kings College hospital Recruiting
London, United Kingdom, WC2R 2LS
Contact: David Rees, Dr   
Principal Investigator: David Rees, Dr         
Sponsors and Collaborators
Institute of Child Health
Principal Investigator: Fenella Kirkham, Dr Institute Of Child Health and Great Ormond Street Hospital
  More Information Identifier: NCT00415727     History of Changes
Other Study ID Numbers: 99NR31
Study First Received: December 22, 2006
Last Updated: December 23, 2006

Additional relevant MeSH terms:
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hematologic Diseases
Genetic Diseases, Inborn processed this record on September 21, 2017